A large pharmaceutical company that has commercialized and/or is developing treatments for cancer, including therapies targeting hormone receptor pathways in cancer cells. These therapies are used for tumors such as ER+ mBC, prostate cancer, and ovarian cancer.  **[0000950170-24-023247_nuvb-20231231.htm:21]** 

AstraZeneca PLC

A large pharmaceutical company involved in the development of cancer therapies, including BET inhibitors for hematological malignancies and solid tumors.  **[0000950170-24-023247_nuvb-20231231.htm:21]** 

Bristol-Myers Squibb Co

A large pharmaceutical company developing cancer treatments, including therapies targeting hormone receptor pathways in cancer cells.  **[0000950170-24-023247_nuvb-20231231.htm:21]** 

Eli Lilly and Co

A large pharmaceutical company that has commercialized and/or is developing treatments for cancer.  **[0000950170-24-023247_nuvb-20231231.htm:21]** 

Merck & Co Inc

A large pharmaceutical company involved in the development of cancer therapies, including hormone receptor-targeting treatments.  **[0000950170-24-023247_nuvb-20231231.htm:21]** 

Novartis AG

Pfizer Inc

A partnership involved in the development of cancer therapies.  **[0000950170-24-023247_nuvb-20231231.htm:21]** 

Regeneron Pharmaceuticals Inc

A company developing clinical-stage BET inhibitors for hematological malignancies and solid tumors.  **[0000950170-24-023247_nuvb-20231231.htm:21]** 

Incyte Corp

AbbVie Inc

Foghorn Therapeutics Inc.

A large pharmaceutical company developing cancer treatments, including therapies targeting hormone receptor pathways in cancer cells and clinical-stage BET inhibitors.  **[0000950170-24-023247_nuvb-20231231.htm:21]** 

David Hung, M.D.

Also at Nuvation Bio Inc

About